secwatch.observer — SEC 8-K summary
======================================

Issuer:     Septerna, Inc. (SEPN)
CIK:        0001984086
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001193125-25-119386
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Septerna & Novo Nordisk partner on oral small molecule obesity drugs; upfront $195M, potential $2.2B
--------------------------------------------------------------------------------

- Collaboration covers up to 5 GPCR targets (GLP-1, GIP, glucagon) for oral small molecule therapies for obesity/T2D.
- Upfront payment of $195M; total potential milestones exceed $2.2B; mid-to-high single-digit royalties on global sales.
- Novo covers 100% of R&D costs; Septerna retains its Native Complex Platform and all other programs.
- Septerna has option to convert to profit-share on one program in lieu of milestones/royalties.
- Phase 1 trial of SEP-631 (MRGPRX2 antagonist for chronic urticaria) expected to start Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1984086/000119312525119386/0001193125-25-119386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1984086/000119312525119386/d940594d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-119386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer